Decreased 1-25 Dihydroxyvitamin D 3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer

Archives of Medical Research

Volumn 41, Issue 3, 2010, Pages 190-194

  Stepien, Tomasz ^a   Krupinski, Roman ^a   Sopinski, Jan ^a   Kuzdak, Krzysztof ^a   Komorowski, Jan ^a   Lawnicka, Hanna ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

1 25 dihydroxyvitamin D 3; 25 hydroxyvitamin D 3; Thyroid cancer.

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYDROXYLATION; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PARATHYROID HORMONE BLOOD LEVEL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; CALCIFEDIOL; CALCITRIOL; CALCIUM; CARCINOMA, PAPILLARY, FOLLICULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; THYROID NEOPLASMS;

EID: 77953485855     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.04.004     Document Type: Article

References (43)

1. Enewold T., Zhu K., Ron E., et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009, 18:784-791.
2. Steliarova-Foucher E., Stiller C.A., Pukkala E., et al. Thyroid cancer incidence and survival among European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2150-2169.
3. Said S., Schlumberger M., Suarez H.G. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J Endocrinol Invest 1994, 17:371-379.
4. Melillo R.M., Cirafici A.M., De Falco V., et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol 2004, 165:511-521.
5. DeLellis R.A. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006, 96:662-669.
6. Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009, 19:468-483.
7. Holick M.F. Sunlight and vitamin D: both good for cardiovascular health. J Gen Intern Med 2002, 17:733-735.
8. Hart G.R., Furniss J.L., D.Laurie D., et al. Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab 2006, 52:335-343.
9. Fife R.S., Sledge G.W., Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett 2007, 120:65-69.
10. Hershberger P.A., Modzelewski R.A., Shurin Z.R., et al. 1,25-dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999, 59:2644-2649.
11. Wu G., Fan R.S., Li W., et al. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:1555-1563.
12. Cross H.S., Peterlik M., Reddy G.S., et al. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol 1997, 62:21-28.
13. Khadzkou K., Buchwald P., Westin G., et al. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 2006, 54:355-361.
14. Segersten U., Holm P.K., Björklund P., et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res 2005, 7:980-986.
15. Feskanich D., Ma D.J., Fuchs C.S., et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004, 13:1502-1508.
16. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005, 16:83-95.
17. Holick M.F. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006, 92:49-59.
18. Crew K.D., Gammon M.D., Steck S.E., et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila Pa) 2009, 2:598-604.
19. Cross H.S., Kallay E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol 2009, 5:493-507.
20. Stolzenberg-Solomon R.Z., Hayes R.B., Horst R.L., et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009, 69:1439-1447.
21. Speers C., Brown C.P. Breast cancer prevention using calcium and vitamin D: a bright future?. J Natl Cancer Inst 2008, 100:1562-1564.
22. 1-S phase-controlling machinery. Mol Endocrinol 2001, 15:1370-1380.
23. Zhuang S.H., Burnstein K.L. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.
24. Stewart L.V., Weigel N.L. Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004, 229:277-284.
25. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
26. Byrne B., Welsh J. Identification of novel mediators of vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J Steroid Biochem Mol Biol 2007, 103:703-707.
27. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001, 276:9101-9107.
28. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 2007, 28:1373-1382.
29. 3 and its nuclear receptor in novel directed therapies for cancer. Gen Physiol Biophys 2006, 25:339-353.
30. Alagbala A.A., Johnson C.S., Trump D.L., et al. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and GH QW-1624F2-2) in squamous cell carcinoma cells. Oncology 2006, 70:483-492.
31. Freedman D.M., Chang S.C., Falk R.T., et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008, 17:889-894.
32. Morishita M., Ohtsuru A., Kumagai A., et al. Vitamin D3 treatment for locally advanced thyroid cancer: a case report. Endocr J 2005, 52:613-616.
33. Ahn J., Peters D., Albanes D., et al. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008, 100:796-804.
34. Abbas S., Linseisen J., Slanger T., et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008, 29:93-99.
35. Masuda S., Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Rev Mol Cancer Ther 2006, 5:797-808.
36. Kliewer S.A., Umesono K., Mangelsdorf D.J., et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355:446-449.
37. Malloy P.J., Feldman D. Vitamin D resistance. Am J Med 1999, 106:355-370.
38. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
39. Lamberg-Allardt C., Valtonen E., Polojarvi M., et al. Characterization of a 1,25-dihydroxy-vitamin D3 receptor in FRTL-5 cells. Evidence for an inhibitory effect of 1,25-dihydroxy-vitamin D3 on thyrotropin-induced iodide uptake. Mol Cell Endocrinol 1991, 81:25-31.
40. Okano K., Usa T., Ohtsuru A., et al. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J 1999, 46:243-252.
41. Liu W., Asa S.L., Fantus I.G., et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 2002, 160:511-519.
42. Verstuyf A., Segaert S., Verlinden L., et al. Recent developments in theuse of vitamin D analogues. Expert Opin Investig Drugs 2000, 9:443-455.
43. Dackiw A.P., Ezzat S., Huang P., et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004, 145:5840-5846.